Connectivity Alterations After Levetiracetam Application

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-25

Study Completion Date

2022-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aimed to analyze the connectivity alterations in brain networks of LGG patients with epilepsy who take levetiracetam at short-term preoperatively.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cognitive Effects of Treatment of Interictal Discharges

NCT00916149

Epilepsy

COMPLETED NA

Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy

NCT00454935

Epilepsy Glioma

UNKNOWN

Effect of Levetiracetam on Brain Excitability

NCT00006191

Healthy Myoclonic Epilepsy

COMPLETED

Levetiracetam for Seizure Prevention After Brain Tumor Surgery

NCT07239115

Postoperative Seizures After Brain Tumor Surgery

NOT_YET_RECRUITING PHASE3

Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS

NCT00152373

Epilepsy, Partial

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Glioma-related epilepsy (GRE) is a very common symptom in patients with diffuse gliomas. Approximately 60% of patients with low-grade gliomas (LGGs) and 40-64% of patients with high-grade gliomas presented with GRE at the onset. Although beneficial for the control of GRE, the overall therapeutic effect was unsatisfied and over 20% of patients still suffered from seizures.

GRE was found to be associated with brain network and functional connectivity. And it has been reported that temporal lobe seizures could induce functional connectivity and decreased network efficiency of brain networks. However, the alterations in functional networks induced by GRE were still unclear. And LGG patients with GRE usually take levetiracetam (LEV) preoperatively, which could effectively reduce abnormal spike activity and further cause connectivity alterations. This makes it more complex to reveal the connectivity alterations of brain networks in LGG patients with GRE.

This study aimed to collect the resting-state functional MRIs of 30 LGG patients who presented with GRE at the onset. Through further applied graph theory analysis, investigators tend to reveal the connectivity alterations of brain networks caused by levetiracetam. The findings of this study will provide a theoretical basis for further study of connectivity alterations of brain networks in patients with GRE.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioma Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with LEV application

LGG patients with GRE take levetiracetam less than 1 month preoperatively. These patients take levetiracetam tablets twice a day, and one tablet at a time. Each levetiracetam tablet contains 500mg levetiracetam.

No interventions assigned to this group

Patients without LEV application

LGG patients with GRE do not take any medicine or receive any treatment preoperatively.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years;
* Histopathological diagnosis with LGG according to the 2016 World Health Organization (WHO) criteria;
* Participants received more than 6 years of school education;
* Presence of GRE, take levetiracetam less than 1 month; or do not take any medicine and receive any treatment;
* No history of biopsy, radiotherapy, or chemotherapy.